__timestamp | Alkermes plc | Catalent, Inc. |
---|---|---|
Wednesday, January 1, 2014 | 447875000 | 1229100000 |
Thursday, January 1, 2015 | 483393000 | 1215500000 |
Friday, January 1, 2016 | 519270000 | 1260500000 |
Sunday, January 1, 2017 | 567637000 | 1420800000 |
Monday, January 1, 2018 | 601826000 | 1710800000 |
Tuesday, January 1, 2019 | 693218000 | 1712900000 |
Wednesday, January 1, 2020 | 572904000 | 2111000000 |
Friday, January 1, 2021 | 603913000 | 2646000000 |
Saturday, January 1, 2022 | 218108000 | 3188000000 |
Sunday, January 1, 2023 | 253037000 | 3216000000 |
Monday, January 1, 2024 | 3428000000 |
In pursuit of knowledge
In the ever-evolving pharmaceutical landscape, understanding cost structures is crucial. From 2014 to 2023, Catalent, Inc. and Alkermes plc have shown distinct trends in their cost of revenue. Catalent's expenses have surged by approximately 178%, peaking in 2023, while Alkermes experienced a 44% drop in 2022, followed by a slight recovery in 2023. This divergence highlights Catalent's aggressive growth strategy, possibly driven by increased production and expansion efforts. Meanwhile, Alkermes' fluctuating costs may reflect strategic shifts or market challenges. Notably, Catalent's costs consistently outpaced Alkermes, underscoring its larger operational scale. As we look to 2024, Catalent's data remains robust, while Alkermes' figures are yet to be revealed, leaving room for speculation on future strategies. This analysis offers a window into the financial dynamics shaping these industry players, providing valuable insights for investors and stakeholders.
Comparison of R&D Expenses for Pfizer and AstraZeneca in 2023
Annual Comparison of SG&A Expense Ratio for AstraZeneca, Pfizer, and GlaxoSmithKline
5 Year Trend in Average Market Capitalization for AbbVie
Comparison of R&D Expenses for Pfizer and AstraZeneca in 2023
Comparison of Average SG&A Expense Ratio for AstraZeneca, Pfizer, and GlaxoSmithKline Over the Years
Comparison of Average SG&A Expense Ratio for AstraZeneca, Pfizer, and GlaxoSmithKline Over the Years
Number of Employees for Top 10 Healthcare Companies
Number of Employees for Top 10 Pharma Companies
Average Market Capitalization of Abbvie Annually
5 Year Trend in Market Capitalization for AbbVie
5 Year Trend in Average Market Capitalization for AbbVie
Comparison of Net Income Margin for Glaxosmithkline, AstraZeneca, Takeda, and Eli Lilly Over the Last 8 Quarters